Masur Henry, Kaplan Jonathan E, Holmes King K
National Institutes of Health, Bethesda, Maryland, USA.
Ann Intern Med. 2002 Sep 3;137(5 Pt 2):435-78. doi: 10.7326/0003-4819-137-5_part_2-200209031-00002.
In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) developed guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV); these guidelines were updated in 1997 and 1999. This fourth edition of the guidelines, made available on the Internet in 2001, is intended for clinicians and other health-care providers who care for HIV-infected persons. The goal of these guidelines is to provide evidence-based guidelines for preventing OIs among HIV-infected adults and adolescents, including pregnant women, and HIV-exposed or infected children. Nineteen OIs, or groups of OIs, are addressed, and recommendations are included for preventing exposure to opportunistic pathogens, preventing first episodes of disease by chemoprophylaxis or vaccination (primary prophylaxis), and preventing disease recurrence (secondary prophylaxis). Major changes since the last edition of the guidelines include 1) updated recommendations for discontinuing primary and secondary OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretroviral therapy; 2) emphasis on screening all HIV-infected persons for infection with hepatitis C virus; 3) new information regarding transmission of human herpesvirus 8 infection; 4) new information regarding drug interactions, chiefly related to rifamycins and antiretroviral drugs; and 5) revised recommendations for immunizing HIV-infected adults and adolescents and HIV-exposed or infected children.
1995年,美国公共卫生服务部(USPHS)和美国传染病学会(IDSA)制定了预防人类免疫缺陷病毒(HIV)感染者机会性感染(OIs)的指南;这些指南于1997年和1999年进行了更新。2001年在互联网上发布的本版指南第四版,面向照顾HIV感染者的临床医生和其他医疗服务提供者。这些指南的目标是为预防HIV感染的成人和青少年(包括孕妇)以及HIV暴露或感染儿童的机会性感染提供循证指南。本指南涉及19种机会性感染或机会性感染组,并包括预防接触机会性病原体、通过化学预防或疫苗接种预防疾病首发(一级预防)以及预防疾病复发(二级预防)的建议。自上一版指南以来的主要变化包括:1)对于因抗逆转录病毒治疗导致CD4 + T淋巴细胞计数增加的患者,更新了停止一级和二级机会性感染预防的建议;2)强调对所有HIV感染者进行丙型肝炎病毒感染筛查;3)关于人类疱疹病毒8型感染传播的新信息;4)关于药物相互作用的新信息,主要与利福霉素和抗逆转录病毒药物有关;5)修订了针对HIV感染的成人和青少年以及HIV暴露或感染儿童的免疫接种建议。